辛伐他汀对COPD稳定期患者的干预作用临床研究  

The effects of Simvastatin intervention in patients with chronic obstructive pulmonary disease in stationary phase

作　　者：陈植涛[1] 唐盛发[1] 

机构地区：[1]中国人民解放军第181医院侨宾楼综合病区,广西桂林541001

出　　处：《右江民族医学院学报》2011年第4期420-422,共3页Journal of Youjiang Medical University for Nationalities

摘　　要：目的探讨辛伐他汀对慢性阻塞性肺疾病(COPD)稳定期患者的影响及作用机制。方法随机将48例COPD稳定期患者分为干预组和对照组,干预组给予辛伐他汀20mg顿服,治疗8周,于治疗前、后记录临床症状得分并检查肺功能、C-反应蛋白(CRP)及白介素-6(IL-6)的含量。结果治疗后干预组与治疗前及治疗后对照组临床症状得分、CRP较治疗前明显降低,差异有显著性(P<0.05),对照组治疗前后差异无显著性;治疗前后干预组、对照组及两组相比,FEV1、FEV1%及IL-6差异无显著性(P>0.05)。结论短期辛伐他汀治疗能改善COPD患者临床症状及降低CRP水平,但不能改善肺功能及降低IL-6水平,辛伐他汀对COPD的疗效及作用机制仍未明确。Objective To investigate the functional mechanism and impact of simvastatin intervention in patients with chronic obstructive pulmonary disease （COPD） in stationary phase.Methods 48 patients with COPD in stationary phase were randomly divided into intervention group and control group.The intervention group was given oral simvastatin 20mg,once daily,8 weeks for a cycle.The clinical symptom scores,pulmonary function and the levels of plasma C-reactive protrin（CRP）,interleukin-6（IL-6） were recorded before and after treatment.Results The clinical symptom scores and CRP levels decreased in interventiong group after treatment;compared to that before treatment,and compared interventiong group after treatment to control group after treatment,there was statisticat difference（P0.05）;in control group,compared before treatment to after treatment,there was no statisticat difference.In comparison of FEV1,FEV1% and IL6 levels,in intervention group and in control group between before and after treatment,between the two groups also,there were not statisticat differences（P0.05）.Conclusion Short-term simvastatin treatment can improve the clinical symptons and reduce the CRP levels in patients with COPD,but can not improve lung function and reduce IL-6 levels,the effectiveness and mechanism of simvastatin in treatment of COPD is still not clear.

关 键 词：肺疾病 慢性阻塞性 斯伐他汀 干预 

分 类 号：R563[医药卫生—呼吸系统] R976.6[医药卫生—内科学]